1. Home
  2. BESS vs LEXX Comparison

BESS vs LEXX Comparison

Compare BESS & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BESS

Bimergen Energy Corporation Common Stock

N/A

Current Price

$2.83

Market Cap

16.2M

Sector

N/A

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.99

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BESS
LEXX
Founded
1998
2004
Country
United States
Canada
Employees
3
7
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2M
16.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BESS
LEXX
Price
$2.83
$0.99
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
36.8K
180.1K
Earning Date
03-31-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.06
$0.46
52 Week High
$3.60
$1.67

Technical Indicators

Market Signals
Indicator
BESS
LEXX
Relative Strength Index (RSI) 50.70 64.93
Support Level $2.50 $0.98
Resistance Level $3.23 $1.05
Average True Range (ATR) 0.38 0.10
MACD 0.04 0.01
Stochastic Oscillator 58.60 83.33

Price Performance

Historical Comparison
BESS
LEXX

About BESS Bimergen Energy Corporation Common Stock

Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: